The KAT6B Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human KAT6B gene in the A-549 lung adenocarcinoma cell line. This product provides a genetically diverse pool of cells with disrupted KAT6B function, enabling robust analysis of gene-dependent phenotypes without clonal bias. By ablating the histone acetyltransferase activity of KAT6B, researchers can investigate its roles in chromatin remodeling and transcriptional regulation within an epithelial cancer context.
The A-549 host cell line, established from a 58-year-old male with lung adenocarcinoma, serves as a well-characterized model for non-small cell lung cancer and type II alveolar epithelial biology. These p53-proficient, adherent cells retain key signaling pathways relevant to tumorigenesis, making them suitable for dissecting epigenetic contributions to lung cancer progression. Their surfactant-producing phenotype adds value for studies intersecting differentiation and malignancy.
KAT6B encodes a histone acetyltransferase that acetylates histone H3 at K14 and K23 and non-histone proteins such as p53. It operates in complexes with BRPF1, ING5, and EAF6, acting as a transcriptional coactivator downstream of RUNX1, TGF???, and BMP signals. KAT6B drives expression of CDKN1A, HOXA cluster genes, and other p53 targets, thereby coordinating cell cycle arrest, apoptosis, and differentiation. Knockout of KAT6B eliminates its enzymatic function, leading to reduced histone acetylation at target loci, impaired p53 coactivation, and transcriptional dysregulation.
Within the A-549 background, loss of KAT6B compromises p53-dependent responses and CDKN1A induction, potentially enhancing proliferative capacity and resistance to apoptosis. The model enables dissection of KAT6B??s influence on TGF??? and Notch signaling crosstalk, which may affect epithelial-mesenchymal transition and stemness. This polyclonal knockout system is valuable for assessing how epigenetic perturbations alter lung cancer cell behavior and for validating histone acetylation as a therapeutic node.
Typical applications include western blotting for H3K14ac and H3K23ac, RT?qPCR for CDKN1A and HOXA expression, ChIP?qPCR for histone mark profiling, and immunofluorescence for KAT6B/acetyl-p53 localization. Additional uses cover cell proliferation and apoptosis assays, flow cytometry for cell cycle analysis, and drug screening targeting acetyltransferase pathways or downstream effectors. The model is also relevant to developmental disorder research, such as Ohdo syndrome. For further details, please contact Ascent Research.
